研究者業績

阿部 朋行

アベ トモユキ  (Tomoyuki ABE)

基本情報

所属
自治医科大学 先端医療技術開発センター オープンサイエンスラボラトリー 講師
学位
農学博士(東京農工大学)

researchmap会員ID
B000237716

外部リンク

論文

 24
  • Tomoyuki Abe, Kazuhiro Endo, Yutaka Hanazono, Eiji Kobayashi
    International Journal of Translational Medicine 4(3) 570-583 2024年9月  査読有り筆頭著者
  • Tomoyuki Abe, Kazuhiro Endo, Yutaka Hanazono, Eiji Kobayashi
    International Journal of Molecular Sciences 25(16) 8609 2024年8月7日  査読有り筆頭著者
    Luminescent technology based on the luciferin-luciferase reaction has been extensively employed across various disciplines as a quantitative imaging modality. Owing to its non-invasive imaging capacity, it has evolved as a valuable in vivo bioimaging tool, particularly in small animal models in fields such as gene and cell therapies. We have previously successfully generated rats with a systemic expression of the luciferase gene at the Rosa26 locus. In this study, we transplanted bone marrow from these rats into micro-mini pigs and used in vivo imaging to non-invasively analyze the dynamics of the transplanted cells. In addition, we established that the rat-to-pig transplantation system is a discordant system, similar to the pig-to-human transplantation system. Thus, rat-to-pig transplantation may provide a clinically appropriate large animal model for pig-to-human xenotransplantation.
  • Tomoyuki Abe, Borjigin Sarentonglaga, Yoshikazu Nagao
    Animal Science Journal 95(1) e13945 2024年  査読有り筆頭著者責任著者
    Sheep are typically considered as industrial animals that provide wool and meals. However, they play a significant role in medical research in addition to their conventional use. Notably, sheep fetuses are resistant to surgical invasions and can endure numerous manipulations, such as needle puncture and cell transplantation, and surgical operations requiring exposure beyond the uterus. Based on these distinguishing characteristics, we established a chimeric sheep model capable of producing human/monkey pluripotent cell-derived blood cells via the fetal liver. Furthermore, sheep have become crucial as human fetal models, acting as platforms for developing and improving techniques for intrauterine surgery to address congenital disorders and clarifying the complex pharmacokinetic interactions between mothers and their fetuses. This study emphasizes the significant contributions of fetal sheep to advancing human disease understanding and treatment strategies, highlighting their unique characteristics that are not present in other animals.
  • Yohei Tomaru, Hisashi Sugaya, Tomokazu Yoshioka, Norihito Arai, Tomoyuki Abe, Yuta Tsukagoshi, Hiroshi Kamada, Masashi Yamazaki, Hajime Mishima
    Journal of Pediatric Orthopedics. Part B 2023年5月22日  査読有り
    This preliminary study investigated the efficacy and safety of bone marrow-derived mesenchymal stem cell transplantation in a piglet Legg-Calve-Perthes disease (LCPD) model. The LCPD model was induced in two Landrace piglets (6- and 7-week-old, weighing 12 and 17 kg, respectively) by ligaturing the femoral neck. In the first piglet, the natural LCPD course was observed. In the second piglet, 4 weeks after ligaturing the femoral neck, simple medium and medium containing 2.44 × 107 bone marrow-derived mesenchymal stem cells were transplanted into the right and left femoral heads after core decompression, respectively. Plain radiographs were obtained every 4 weeks, and the epiphyseal quotient was calculated by dividing the maximum epiphysis height by the maximum epiphysis diameter. The piglets were sacrificed at 14 weeks postoperatively. The femoral heads were extracted and evaluated grossly, pathologically, and by using computed tomography. The transplanted cell characteristics were evaluated using flow cytometry. Flattening of the epiphysis was observed in both femoral heads of the first piglet and only in the right hip of the second piglet. The epiphyseal quotients immediately and at 14 weeks postoperatively in the right femoral head of the second piglet were 0.40 and 0.14, respectively, while those of the left femoral head were 0.30 and 0.42, respectively. Hematoxylin and eosin staining did not reveal physeal bar or tumor cell formation. The transplanted cells were 99.2%, 65.9%, 18.2%, and 0.16% positive for CD44, CD105, CD29, and CD31, respectively. Core decompression combined with bone marrow-derived mesenchymal stem cell transplantation prevented epiphyseal collapse.
  • Takafumi Hiramoto, Yuji Kashiwakura, Morisada Hayakawa, Nemekhbayar Baatartsogt, Nobuhiko Kamoshita, Tomoyuki Abe, Hiroshi Inaba, Hiroshi Nishimasu, Hideki Uosaki, Yutaka Hanazono, Osamu Nureki, Tsukasa Ohmori
    Communications Medicine 3(1) 2023年4月19日  査読有り
    Abstract Background Base editing via CRISPR-Cas9 has garnered attention as a method for correcting disease-specific mutations without causing double-strand breaks, thereby avoiding large deletions and translocations in the host chromosome. However, its reliance on the protospacer adjacent motif (PAM) can limit its use. We aimed to restore a disease mutation in a patient with severe hemophilia B using base editing with SpCas9-NG, a modified Cas9 with the board PAM flexibility. Methods We generated induced pluripotent stem cells (iPSCs) from a patient with hemophilia B (c.947T>C; I316T) and established HEK293 cells and knock-in mice expressing the patient’s F9 cDNA. We transduced the cytidine base editor (C>T), including the nickase version of Cas9 (wild-type SpCas9 or SpCas9-NG), into the HEK293 cells and knock-in mice through plasmid transfection and an adeno-associated virus vector, respectively. Results Here we demonstrate the broad PAM flexibility of SpCas9-NG near the mutation site. The base-editing approach using SpCas9-NG but not wild-type SpCas9 successfully converts C to T at the mutation in the iPSCs. Gene-corrected iPSCs differentiate into hepatocyte-like cells in vitro and express substantial levels of F9 mRNA after subrenal capsule transplantation into immunodeficient mice. Additionally, SpCas9-NG–mediated base editing corrects the mutation in both HEK293 cells and knock-in mice, thereby restoring the production of the coagulation factor. Conclusion A base-editing approach utilizing the broad PAM flexibility of SpCas9-NG can provide a solution for the treatment of genetic diseases, including hemophilia B.
  • 阿部朋行, 長尾慶和
    医学のあゆみ 279(4) 310-316 2021年  筆頭著者責任著者
  • Tomoyuki Abe, Hideki Uosaki, Hiroaki Shibata, Hiromasa Hara, Borjigin Sarentonglaga, Yoshikazu Nagao, Yutaka Hanazono
    Experimental Hematology 95 46-57 2021年1月1日  査読有り筆頭著者責任著者
    We report that a sheep fetal liver provides a microenvironment for generating hematopoietic cells with long-term engrafting capacity and multilineage differentiation potential from human induced pluripotent stem cell (iPSC)-derived hemogenic endothelial cells (HEs). Despite the promise of iPSCs for making any cell types, generating hematopoietic stem and progenitor cells (HSPCs) is still a challenge. We hypothesized that the hematopoietic microenvironment, which exists in fetal liver but is lacking in vitro, turns iPSC-HEs into HSPCs. To test this, we transplanted CD45-negative iPSC-HEs into fetal sheep liver, in which HSPCs first grow. Within 2 months, the transplanted cells became CD45 positive and differentiated into multilineage blood cells in the fetal liver. Then, CD45-positive cells translocated to the bone marrow and were maintained there for 3 years with the capability of multilineage differentiation, indicating that hematopoietic cells with long-term engraftment potential were generated. Moreover, human hematopoietic cells were temporally enriched by xenogeneic donor-lymphocyte infusion into the sheep. This study could serve as a foundation to generate HSPCs from iPSCs.
  • 阿部 朋行, 花園 豊
    Organ Biology 27(2) 167-172 2020年7月  筆頭著者責任著者
  • Suvd Byambaa, Hideki Uosaki, Hiromasa Hara, Yasumitsu Nagao, Tomoyuki Abe, Hiroaki Shibata, Osamu Nureki, Tsukasa Ohmori, Yutaka Hanazono
    Experimental Animals 69(2) 189-198 2020年4月24日  査読有り
    X-linked severe combined immunodeficiency (X-SCID) is an inherited genetic disorder. A majority of X-SCID subjects carries point mutations in the Interleukin-2 receptor gamma chain (IL2RG) gene. In contrast, Il2rg-knockout mice recapitulating X-SCID phenotype lack a large part of Il2rg instead of point mutations. In this study, we generated novel X-SCID mouse strains with small insertion and deletion (InDel) mutations in Il2rg by using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9. To this end, we injected Streptococcus pyogenes Cas9 (SpCas9) mRNA and single guide RNA targeting the exon 2, 3 or 4 of Il2rg into mouse zygotes. In the F0 generation, we obtained 35 pups and 25 out of them were positive for Surveyor assay, and most of mutants displayed dramatic reductions of T and B lymphocytes in the peripheral blood. By amplicon sequencing, 15 out of 31 founder mice were determined as monoallelic mutants with possible minor mosaicisms while 10 mice were mosaic. Finally, we established new strains with 7-nucleotide deletion and 1-nucleotide insertions in the exon 2 and the exons 3 and 4, respectively. Although no IL2RG protein was detected on T cells of exons 3 and 4 mutants, IL2RG protein was unexpectedly detected in the exon 2 mutants. These data indicated that CRISPR/Cas9 targeting Il2rg causes InDel mutations effectively and generates genetically X-SCID mice. Genetic mutations, however, did not necessarily grant phenotypical alteration, which requires an intensive analysis after establishing a strain to confirm their phenotypes.
  • Nawin Chanthra, Tomoyuki Abe, Matthew Miyamoto, Kiyotoshi Sekiguchi, Chulan Kwon, Yutaka Hanazono, Hideki Uosaki
    Scientific Reports 10(1) 4249-4249 2020年3月6日  査読有り
    Pluripotent stem cell-derived cardiomyocytes (PSC-CMs) hold great promise for disease modeling and drug discovery. However, PSC-CMs exhibit immature phenotypes in culture, and the lack of maturity limits their broad applications. While physical and functional analyses are generally used to determine the status of cardiomyocyte maturation, they could be time-consuming and often present challenges in comparing maturation-enhancing strategies. Therefore, there is a demand for a method to assess cardiomyocyte maturation rapidly and reproducibly. In this study, we found that Myomesin-2 (Myom2), encoding M-protein, is upregulated postnatally, and based on this, we targeted TagRFP to the Myom2 locus in mouse embryonic stem cells. Myom2-RFP+ PSC-CMs exhibited more mature phenotypes than RFP- cells in morphology, function and transcriptionally, conductive to sarcomere shortening assays. Using this system, we screened extracellular matrices (ECMs) and identified laminin-511/521 as potent enhancers of cardiomyocyte maturation. Together, we developed and characterized a novel fluorescent reporter system for the assessment of cardiomyocyte maturation and identified potent maturation-enhancing ECMs through this simple and rapid assay. This system is expected to facilitate use of PSC-CMs in a variety of scientific and medical investigations.
  • Asuka Hara, Tomoyuki Abe, Atsushi Hirao, Kazuhiro Sanbe, Hiromichi Ayakawa, Borjigin Sarantonglaga, Mio Yamaguchi, Akane Sato, Atchalalt Khurchabilig, Kazuko Ogata, Rika Fukumori, Shoei Sugita, Yoshikazu Nagao
    Journal of Veterinary Medical Science 80(2) 263-271 2018年2月1日  査読有り
  • Naoki Osada, Jiro Kikuchi, Takashi Umehara, Shin Sato, Masashi Urabe, Tomoyuki Abe, Nakanobu Hayashi, Masahiko Sugitani, Yutaka Hanazono, Yusuke Furukawa
    Oncotarget 9(5) 6450-6462 2018年  査読有り
  • Hiromasa Hara, Hiroaki Shibata, Kazuaki Nakano, Tomoyuki Abe, Hideki Uosaki, Takahiro Ohnuki, Shuji Hishikawa, Satoshi Kunita, Masahito Watanabe, Osamu Nureki, Hiroshi Nagashima, Yutaka Hanazono
    Experimental Animals 67(2) 139-146 2018年  査読有り
  • Tomoyuki Abe, Yoshikazu Matsuoka, Yoshikazu Nagao, Yoshiaki Sonoda, Yutaka Hanazono
    International Journal of Hematology 106(5) 631-637 2017年11月  査読有り筆頭著者
  • Tomoyuki Abe, Shota Kono, Takahiro Ohnuki, Shuji Hishikawa, Satoshi Kunita, Yutaka Hanazono
    Experimental Animals 65(4) 345-351 2016年  査読有り筆頭著者
  • Tomoyuki Abe, Yutaka Hanazono, Yoshikazu Nagao
    Experimental Animals 63(4) 475-481 2014年10月  査読有り筆頭著者
  • Yoshihisa Mizukami, Tomoyuki Abe, Hiroaki Shibata, Yukitoshi Makimura, Shuh-hei Fujishiro, Kimihide Yanase, Shuji Hishikawa, Eiji Kobayashi, Yutaka Hanazono
    PLOS ONE 9(6) e98319 2014年6月  査読有り
  • Shuh-hei Fujishiro, Kazuaki Nakano, Yoshihisa Mizukami, Takuya Azami, Yoshikazu Arai, Hitomi Matsunari, Rikiya Ishino, Takashi Nishimura, Masahito Watanabe, Tomoyuki Abe, Yutaka Furukawa, Kazuhiro Umeyama, Shinya Yamanaka, Masatsugu Ema, Hiroshi Nagashima, Yutaka Hanazono
    Stem Cells and Development 22(3) 473-482 2013年2月  査読有り
  • Tomoyuki Abe, Shigeo Masuda, Yujiro Tanaka, Suguru Nitta, Yoshihiro Kitano, Satoshi Hayashi, Yutaka Hanazono, Yoshikazu Nagao
    Experimental Hematology 40(6) 436-444 2012年6月  査読有り筆頭著者
  • Shigeo Masuda, Satoshi Hayashi, Naohide Ageyama, Hiroaki Shibata, Tomoyuki Abe, Yoshikazu Nagao, Yutaka Hanazono
    Transplantation 92(2) e5-6; author reply e6-7-6; author reply e6 2011年7月27日  査読有り
  • Tomoyuki Abe, Shigeo Masuda, Hiroshi Ban, Satoshi Hayashi, Yasuji Ueda, Makoto Inoue, Mamoru Hasegawa, Yoshikazu Nagao, Yutaka Hanazono
    EXPERIMENTAL HEMATOLOGY 39(1) 47-54 2011年1月  査読有り
  • Yujiro Tanaka, Shigeo Masuda, Tomoyuki Abe, Satoshi Hayashi, Yoshihiro Kitano, Yoshikazu Nagao, Yutaka Hanazono
    TRANSPLANTATION 90(4) 462-463 2010年8月  査読有り
  • Yoshikazu Nagao, Tomoyuki Abe, Hideaki Hasegawa, Yujiro Tanaka, Kyoko Sasaki, Yoshihiro Kitano, Satoshi Hayashi, Yutaka Hanazono
    CLONING AND STEM CELLS 11(2) 281-285 2009年6月  査読有り
  • Yujiro Tanaka, Shinichiro Nakamura, Hiroaki Shibata, Yukiko Kishi, Tamako Ikeda, Shigeo Masuda, Kyoko Sasaki, Tomoyuki Abe, Satoshi Hayashi, Yoshihiro Kitano, Yoshikazu Nagao, Yutaka Hanazono
    STEM CELLS AND DEVELOPMENT 17(2) 367-381 2008年4月  査読有り

MISC

 45

共同研究・競争的資金等の研究課題

 8

産業財産権

 1